ERH (enhancer of rudimentary homolog) is a highly conserved small molecule protein involved in multiple aspects of mRNA metabolism and cell cycle regulation. Functionally, ERH acts as a protein partner in human cells, participating in pyrimidine metabolism and serving as a transcriptional repressor 1. At the molecular level, ERH is integrated into protein complexes and plays roles in mRNA splicing and export from the nucleus, as well as microRNA hairpin processing 1. Recent proteomic mapping identified ERH as an RNA-binding protein component of the mRNA life cycle, with its splicing and export functions characterized through its interactions with other RNA-processing proteins 2. Beyond mRNA processing, ERH participates in DNA damage repair mechanisms and erythroid differentiation 1. Regarding disease relevance, ERH has been implicated in cancer biology, where it participates in cell cycle regulation 1. However, no tumor-targeted therapeutic drugs or validated therapies based on ERH expression alterations have been clinically developed to date 1. The clinical significance of ERH remains largely exploratory, with its potential as a biomarker or therapeutic target requiring further investigation in oncology and other disease contexts.